stockrow
Saturday 7 November 2026
Export SLN’s income statement to Excel — free account
Silence Therapeutics PLC Sponsored ADR
Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024.
- Revenue
- +197.2%
- EPS
- +54.4%
- Free cash flow
- +107.0%
Quarter to June 2026, against a year earlier
19.73
0.01
+0.05%
Follow SLN
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 5 | 5 | 3 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Altman Z-Score |
(4.82) | (0.30) | (1.80) | (1.14) | (0.27) | 0.04 | — | — | — | — |
P/S ratio |
513.72 | 7.36 | 21.74 | 21.85 | 20.33 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(12.42) | (2.15) | (10.73) | (6.19) | (5.80) | (5.79) | — | — | — | 31.74 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Beneish M-Score |
45.78 | (1.86) | (2.39) | (1.55) | (4.17) | — | — | — | — | — |
P/Operating CF |
(16.61) | (11.58) | (46.90) | (25.59) | (52.53) | (44.15) | 374.87 | — | 374.87 | 374.87 |
P/B ratio |
4.61 | 2.37 | 31.29 | 17.32 | 45.82 | 52.52 | 12.43 | — | 12.43 | 12.43 |
Price to Tangible BV |
5.59 | 2.56 | 59.06 | 27.82 | 429.28 | 518.60 | 17.74 | — | 17.74 | 17.74 |
EV/Sales |
361.63 | 3.95 | 19.57 | 17.78 | 16.50 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/Operating CF |
(3.25) | (2.53) | (12.52) | (6.85) | (36.56) | (108.15) | (291.34) | — | (291.34) | (291.34) |
EV/FCF |
(3.24) | (2.52) | (12.51) | (6.83) | (36.56) | (108.15) | (291.34) | — | (291.34) | (291.34) |
Quick Ratio |
7.87 | 10.27 | 4.10 | 3.96 | 5.33 | 2.81 | 3.84 | 7.57 | 16.95 | 25.92 |
Current Ratio |
8.72 | 11.14 | 4.62 | 4.41 | 5.69 | 2.99 | 3.88 | 7.70 | 17.14 | 26.09 |
Net Debt/EBITDA |
0.94 | 2.35 | 1.08 | 1.48 | 1.62 | 1.10 | 1.56 | 1.26 | 3.24 | 3.36 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.27 | 0.25 | 0.16 | 0.14 | 0.08 | 0.01 | 0.00 | 0.00 | 0.01 |
Operating CF/Net income |
0.70 | 1.49 | 0.91 | 1.12 | (0.17) | 0.33 | (0.09) | 0.91 | 5.94 | 1.17 |
Capex/Depreciation |
(0.10) | (0.36) | (0.09) | (0.91) | (3.12) | (1.03) | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | (24.05) | (1,034.50) | (881.10) | (110.99) | (1,686.05) | (1,054.67) | (1,920.53) | (15.42) |
| (90.27%) | (58.08%) | (220.02%) | (256.66%) | (464.06%) | (173.84%) | (70.17%) | (41.16%) | (3.46%) | (15.14%) | |
| (53.05%) | (28.13%) | (42.97%) | (37.76%) | (44.66%) | (48.07%) | (103.54%) | (47.55%) | (8.18%) | (14.55%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(83.11%) | (26.29%) | (65.53%) | (52.62%) | (53.91%) | (62.65%) | (66.35%) | (72.49%) | (3.50%) | (20.20%) |
Average Days of Receivables |
14,369.51 | 214.05 | 262.21 | 329.46 | 213.91 | 2,187.88 | 5,465.97 | 0.00 | 47,122.21 | 1,285.08 |
Research and Development Expense of Revenue |
12,120.39% | 156.93% | 179.94% | 203.45% | 247.80% | 368.85% | 5,452.94% | 0.00% | 49,537.38% | 1,130.26% |
Selling, General and Administrative Expense of Revenue |
3,997.14% | 62.15% | 82.87% | 112.05% | 161.16% | 255.21% | 3,765.34% | 0.00% | 29,368.93% | 475.71% |
Intangible Assets out of Total Assets |
0.08 | 0.05 | 0.09 | 0.08 | 0.08 | 0.09 | 0.00 | 0.21 | 0.00 | 0.14 |
Share Based Compensation of Revenue |
1,444.36% | 37.70% | 51.43% | 58.58% | 69.53% | 80.22% | 0.00% | — | 0.00% | 0.00% |
Graham Net Nets |
0.17 | 0.37 | 0.01 | 0.03 | 0.00 | 0.00 | 0.05 | — | 0.05 | 0.05 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Earnings Yield |
(30.76%) | (13.81%) | (7.87%) | (10.62%) | (18.22%) | (13.19%) | (8.70%) | — | (8.70%) | (8.70%) |
Free Cash Flow Yield |
(21.70%) | (21.32%) | (7.20%) | (11.92%) | (2.22%) | (0.85%) | (0.29%) | — | (0.29%) | (0.29%) |
Revenue per Share |
0.01 | 0.94 | 0.85 | 0.67 | 0.58 | 0.26 | 0.02 | 0.00 | 0.00 | 0.04 |
Operating CF per Share |
(1.32) | (1.46) | (1.33) | (1.75) | 0.32 | (0.51) | 0.11 | (1.22) | (0.59) | (0.52) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | (0.06) | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.32) | (1.47) | (1.33) | (1.76) | 0.25 | (0.53) | 0.11 | (1.22) | (0.59) | (0.52) |
Cash per Share |
1.80 | 3.19 | 1.85 | 2.73 | 3.41 | 1.83 | 2.33 | 1.85 | 2.79 | 2.03 |
Shareholders Equity per Share |
1.32 | 2.90 | 0.59 | 0.85 | 0.40 | 0.43 | 1.46 | 2.44 | 3.39 | 2.82 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.32 | 2.90 | 0.59 | 0.85 | 0.40 | 0.43 | 1.46 | 2.44 | 3.39 | 2.82 |
Free Cash Flow |
(62.33) | (67.85) | (49.52) | (56.77) | 7.52 | (14.49) | 2.82 | (28.58) | (16.73) | (12.23) |
Working Capital |
105.05 | 170.54 | 80.82 | 92.45 | 97.86 | 65.26 | 48.48 | 41.91 | 78.40 | 49.88 |
Capital Expenditures |
(0.05) | (0.21) | (0.06) | (0.54) | (1.83) | (0.66) | (0.02) | (0.32) | (0.30) | (0.66) |
Net Current Asset Value |
49.52 | 118.75 | 5.70 | 13.93 | (1.84) | (0.66) | 21.43 | 41.91 | 78.40 | 49.88 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Capex to Sales |
0.10 | 0.00 | 0.00 | 0.03 | 0.11 | 0.09 | 0.00 | — | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.33 | 0.32 | 0.22 | 0.22 | 0.44 | 0.76 | 0.45 | 0.35 | 0.23 |
Cash ROIC |
(42.28%) | (24.12%) | (54.55%) | (49.24%) | 6.67% | (23.51%) | 2.97% | (28.42%) | (9.59%) | (10.63%) |
Accounts Receivable Turnover |
0.02 | 1.80 | 1.50 | 1.47 | 0.65 | 0.29 | 0.08 | 0.00 | 0.01 | 0.32 |
Accounts Payable Turnover |
0.01 | 0.74 | 0.83 | 0.88 | 0.81 | 0.71 | 0.00 | 0.50 | 1.01 | 0.60 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
22,674.14 | 506.83 | 440.74 | 423.81 | 527.87 | 794.81 | 0.00 | 1,002.24 | 409.12 | 621.68 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
23.69 | 24.05 | 21.14 | 14.77 | 26.09 | 24.15 | 5.06 | 3.79 | 3.47 | 3.00 |
Average Payables |
14.88 | 15.97 | 15.58 | 15.23 | 12.67 | 6.82 | 2.50 | 1.36 | 0.75 | 0.64 |
Average Assets |
167.04 | 161.04 | 126.21 | 132.62 | 121.33 | 86.94 | 31.75 | 66.19 | 34.44 | 71.61 |
Average Common Equity |
98.16 | 78.01 | 24.65 | 19.51 | 11.68 | 24.04 | 46.84 | 76.47 | 81.30 | 68.82 |
Columns are period end dates · fundamentals updated 26 Oct 2026